

# Multifrequency Laser-Assisted Lipolysis in a Patient with Excessive Redundant Skin Post Roux-en-Y Gastric Bypass: A Clinical Case and Literature Review

Lipólisis asistida por láser multifrecuencia en un paciente con piel redundante excesiva después de un bypass gástrico en y de Roux: un caso clínico y una revisión de la literatura

Gabriel Cubillos<sup>1a</sup>, Andrés Miguel Ortegon Pulido<sup>2a</sup>, Neidalis Vásquez<sup>3a</sup>, Valmore Bermúdez<sup>4b,c</sup>

## SUMMARY

*Patients undergoing bariatric procedures experience massive weight loss accompanied by significant soft tissue laxity throughout the body. In such cases, aesthetic surgery aims to assist in regaining body contour. However, the impact of traditional surgical procedures on redundant tissue results in extensive scars, raising concerns and dissatisfaction among patients. Multifrequency laser-assisted lipolysis is a novel modality that has proven effective in reducing residual fat and inducing skin tightening with minimal scarring. This case presents the surgical management using liposuction and multifrequency laser for the*

*treatment of redundant skin and localized remnants of abdominal adipose tissue following Roux-en-Y gastric bypass due to a diagnosis of grade III obesity and massive weight loss secondary to this procedure with an excellent aesthetics result and prompt recovery time without surgical or medical complications.*

**Keywords:** Liposuction, laser-assisted lipolysis, obesity, multifrequency laser, adipose tissue.

## RESUMEN

*Los pacientes sometidos a procedimientos bariátricos experimentan una pérdida masiva de peso acompañada de una laxitud significativa de los tejidos blandos en todo el cuerpo. En estos casos, la cirugía estética tiene como objetivo ayudar a recuperar el*

DOI: <https://doi.org/10.47307/GMC.2024.132.1.20>

ORCID: <https://orcid.org/0000-0001-6765-4891><sup>1</sup>

ORCID: <https://orcid.org/0000-0001-5000-3777><sup>2</sup>

ORCID: <https://orcid.org/0000-0003-0182-9614><sup>3</sup>

ORCID: <https://orcid.org/0000-0003-1880-8887><sup>4</sup>

E-mail: [drgabrielcubillosv@gmail.com](mailto:drgabrielcubillosv@gmail.com)

E-mail: [drandresortegonp@gmail.com](mailto:drandresortegonp@gmail.com)

E-mail: [neidalisvasquez1309@gmail.com](mailto:neidalisvasquez1309@gmail.com)

E-mail: [valmore.bermudez@unisimon.edu.co](mailto:valmore.bermudez@unisimon.edu.co)

Recibido: 26 de noviembre 2023

Aceptado: 5 de febrero 2024

<sup>a</sup>Clínica de Obesidad y envejecimiento, Bogotá, Colombia.

<sup>b</sup>Universidad Simón Bolívar. Facultad de Ciencias de la Salud, Barranquilla, Colombia.

<sup>c</sup>Centro de Investigaciones en Ciencias de la Vida. Universidad Simón Bolívar, Barranquilla, Colombia.

Corresponding author: Gabriel Fernando Cubillos Valencia, MD. Clínica Obesidad y Envejecimiento SAS, Bogotá 110111, Colombia. E-mail: [drgabrielcubillosv@gmail.com](mailto:drgabrielcubillosv@gmail.com)

*contorno corporal. Sin embargo, el impacto de los procedimientos quirúrgicos tradicionales en el tejido redundante produce cicatrices extensas, lo que genera preocupación e insatisfacción entre los pacientes. La lipólisis asistida por láser multifrecuencia es una modalidad novedosa que ha demostrado ser eficaz para reducir la grasa residual e inducir el estiramiento de la piel con cicatrices mínimas. Este caso presenta el manejo quirúrgico mediante liposucción y láser multifrecuencia para el tratamiento de piel redundante y restos localizados de tejido adiposo abdominal posterior a bypass gástrico en Y de Roux por diagnóstico de obesidad grado III y pérdida masiva de peso secundaria a este procedimiento con un excelente resultado estético y pronta recuperación sin complicaciones quirúrgicas ni médicas.*

**Palabras clave:** *Liposucción, lipólisis asistida por láser, obesidad, láser multifrecuencia, tejido adiposo.*

## INTRODUCTION

Obesity is a chronic, progressive, multifactorial, and challenging-to-manage disease whose prevalence has reached pandemic proportions (1-3). The genesis of Obesity involves genetic, metabolic, psychological, and endocrinological factors interacting in different degrees and patterns in each individual, producing a unique obese phenotype known as classical polygenic Obesity (4,5).

Currently, it is clear that Obesity is an independent risk factor for a wide range of related chronic diseases such as metabolic syndrome (6), type 2 diabetes mellitus (T2DM) (7), hypertension (8), dyslipidemias (9), cardiovascular diseases (CVD) (10), respiratory disorders (11), joint diseases (12), psychosocial disorders (13), and even some types of cancer including oesophageal, colon, pancreatic, prostate, and breast (14). All these diseases are likely linked to Obesity through visceral adipose tissue inflammation and, later, in subcutaneous adipose tissue, where the adipocyte becomes dysfunctional due to hypoxia, hyperglycemia, and a high-fat diet. This process leads to a pro-inflammatory adipocyte phenotype characterised by leptin hypersecretion and Interleukine-6 (IL-6), chemokine (C-C motif) ligand 2 (CCL-2), and Nuclear Factor- $\kappa$ B (NF- $\kappa$ B) overexpression, resulting in monocyte infiltration and macrophage polarisation to M2 phenotype (15).

Although achieving significant weight loss is a positive result of anti-obesity treatments, particularly in post-bariatric patients, challenges frequently emerge related to cosmetic concerns stemming from excess skin in areas such as the abdomen, thighs, arms, and chest (16,17). This issue contributes to discontent and poses physical and psychosocial challenges affecting the health and functional well-being of post-bariatric patients. In this context, it is worth noting that at least 70 % of adults report excessive redundant skin (ERS) after bariatric surgery (18-22), and numerous studies have reported an increased prevalence in physical (e.g., skin irritation, pain, infections), psychosocial (e.g., disgust, shame, anxiety), and daily activities (e.g., personal hygiene, dressing) disturbances (18-23). Therefore, addressing ERS is a necessary and crucial step to enhance the quality of life in post-bariatric surgery patients (24-32). For this reason, this study aims to report the results of laser-assisted liposuction in a patient with excessive redundant skin and residual adipose tissue after Roux-en-Y gastric bypass.

## Case Description

A 38-year-old female patient with a Grade II obesity history (Weight: 104 kg, Height: 1.69 meters; BMI of 36.49 kg/m<sup>2</sup>) and impaired fasting glucose (105 mg/dL), and a Roux-en-Y gastric bypass (RYGB) in January 2022. She lost  $\approx$  45 kg in the seven months following the surgery, reaching a stable BMI of 20.70 kg/m<sup>2</sup>. Nevertheless, the patient visited our aesthetic surgery clinic because she was dissatisfied with abdominal skin excess and sagging in her arms, posterior chest, breasts, and inner thighs (Panel 1A), and she sought improvement in her appearance. Due to those mentioned above, the patient was scheduled for a comprehensive evaluation to plan how to solve her aesthetic problem.

During the first medical consultation, a complete medical history was performed, paying special attention to cardio-respiratory examination, endocrine system evaluation, obesity comorbidities, and skin disease rule-out. Therefore, in this stage, a thorough inspection was conducted regarding skin thickness, laxity, and lesions, helping to determine the body areas

requiring an aesthetic procedure. In this regard, a physical skin examination revealed both breasts displaying an elongated, pendulous, and symmetrical appearance. The sternal notch to nipple distance was 24 cm for the right breast and 23 cm for the left breast, indicating Grade 2 breast ptosis. Abundant redundant skin with evident striae less than 2 cm thick was present around the umbilicus, and the lower abdomen was

on abdominal inspection. Palpation revealed a soft, depressible, non-painful abdomen without visceromegaly, confirming an important skin excess and laxity. Both upper limbs exhibit skin excess, particularly on the posterior region of both arms. Lower limbs, while symmetrical, show flaccidity and excess skin on both inner and outer thighs (Panel 1A).



Panel 1. Redundant skin and adipose panniculus evolution at baseline **A:** Patient appearance before laser-assisted lipolysis, front view. A notable presence of surplus skin is evident in the abdomen and arms. Additionally, there is an important residual fat accumulation in the abdomen, hips, thighs, and arms. Furthermore, a bilateral breast elongation required a lift procedure involving the placement of 350 cc implants. **B:** Patient appearance before laser-assisted lipolysis, back view. Similarly, residual lower and upper back, thighs, arms, hips, and buttocks fat accumulation and gynoid lipodystrophy (celullité) are evident.

Cardio-pulmonary examination showed rhythmic heart sounds without murmurs; blood pressure of 125/76 mmHg in the left arm and 123/74 mmHg in the right arm seated, with a heart rate and peripheral pulse of 76 beats per minute. Resting 12-lead ECG shows no abnormalities in routine parameter analysis. Respiratory excursions are full and symmetrical. Lungs resonant to percussion and vesicular breath sounds throughout peripheral lung fields. No rales, rhonchi, wheezes, rubs, or tactile fremitus were normal. The rest of the physical examination and general laboratory studies (Table 1) were within normal limits.

One week later, a second medical consultation with the plastic surgery team was conducted

to review the laboratory findings and discuss surgical approaches to resolve her skin excess. Ultimately, a consensus was reached around a Laser-Assisted Lipolysis (LAL). One week later, a preoperative medical assessment by the anesthesiologist was performed before the surgical procedure.

Finally, four days before surgery, the participant underwent a 40-minute external low-level red (650 nm) and infrared (980 nm) with a Lipolaser device (Lipolaser LPL9002™, Colombia), directly applied to all skin areas to be treated during surgery—this intervention aimed to initiate adipose tissue lysis before the surgical procedure.

MULTIFREQUENCY LASER-ASSISTED LIPOLYSIS

Table 1. Preoperative laboratory test

Test	Result	Normal values
Thyroid stimulant hormone (TSH)	1.71 mLU/mL	0.35-5.1 mLU/mL
Prolactin	28.34 ng/mL	1.2-19.5
Cortisol 8:00 am	9.93 µg/dL	6.4-22.8
<i>Helicobacter pylori</i> IgG	7.03	Negative 9 Undeterminate: 9 - 11 Positive >11
<i>Chlamydia trachomatis</i> IgG	0.93	Negative < 9 Undeterminate: 9 - 11 Positivo mayor a >11
Anti-thyropoxidase Abs (TPO)	<0.25UI/mL	0-35
Fasting blood glucose	76 mg/dL	70-110
Total cholesterol	133 mg/dL	≤ 200 mg/dL
Triacylglycerides	48 mg/dL	≤ 150
Uric acid	3.1 mg/dL	Women: 2.6 - 6 Men: 3.5 - 7.2
Antistreptolisines	49.5 UI/mL	≤ 200
Blood cell count		
Total white blood cells	3,540	4.0 - 10.0
% Neutrophils	55.7 %	39.3 - 73.7
% Lymphocytes	34.8 %	20 - 40
% Monocytes	7.6 %	4.40 - 12.7
% Eosinophils	1.5 %	0.600 - 7.30
% Basophils	0.4 %	0.00 - 1.70
% MID (Mean Inflammatory Distributor)	0.0 %	0.0 - 6.0
Lymphocytes	1.23 x10 <sup>e3</sup> /µL	0.8 - 4.0
Neutrophils	1.98 x10 <sup>e3</sup> /µL	1.63 - 6.9
Monocytes	0.27 x10 <sup>e3</sup> /µL	0.240 - 0.790
Eosinophils	0.05 x10 <sup>e3</sup> /µL	0.030 - 0.440
Basophils	0.01 x10 <sup>e3</sup> /µL	0.00 - 0.80
MID (Mean Inflammatory Distributor)	0.00 x10 <sup>e3</sup> /µL	0.18 - 0.24
Red Blood Cells	4.15 x10 <sup>e3</sup> /µL	5.22 - 6.02
Haemoglobin	12.2 g/dL	13 - 17
Hematocrit	36.1 %	39 - 52
Mean Corpuscular Volume	86.9 fL	82.0 - 96.0
Mean Corpuscular Hemoglobin	29.4 pg	26.0 - 32.0
Mean Corpuscular Hemoglobin Concentration	33.8 g/dL	31.0 - 38.0
Red Cell Distribution Width	14.1 %	11.5 - 14.5
Platelet Count	210 x10 <sup>e3</sup> /µL	150 - 450
Mean Platelet Volume	12.0 fL	7.0 - 11.0
Plateleterit	0.253 %	0.108 - 0.282
Platelet Distribution Width	15.6 10(GSD)	11.5 - 17.0
Prothrombin time	12 sec.	12 - 19
Partial thromboplastin time	32 sec.	25 - 33

**Operative stage**

**Preliminary preparation.** Following a 12-hour fasting period, general anesthesia with profound sedation was administered. Subsequently, the designated areas for intervention were marked, rigorous asepsis and antisepsis procedures were

done in all surgical regions, and surgical drapes were meticulously positioned to maintain sterility.

**Areas selected for intervention.** The addressed regions in this study were as follows: 1. Abdomen, 2. Lumbar region; 3. Anterior and posterior (dorsal) thorax (with pexy and breast

prosthesis placement in women), 4. Arms and, 6. Legs.

**Patient setup.** In the case of the lumbar region approach, the patient was placed in a prone decubitus position. The surgical table was set at an angle inducing slight vertebral column flexion to optimize access to the lumbar region. Subsequently, incision sites were marked along the maximal subcutaneous fat fold axis. For the abdominal region approach, the patient was positioned in a supine decubitus position with a slight hyperextension, and a substernal incision was made to provide easy and secure access to the costal margin and the upper hemi-abdominal region.

Additionally, two small incisions were made at the suprapubic line to access the lower hemi-abdomen, and bilateral incisions were made in both the flanks and iliac crest. In the case of the anterior chest, incisions were made at the axillary level, and for the posterior chest, two incisions were made at the scapular and infrascapular lines. In the legs, incisions were made on both the inner part of the thighs and knees. In the case of the gluteal regions, the first incision was on

the top of this region, and the other one was in the lower gluteal line. In the case of face LAL, two incisions were made at the infraauricular zone and chin.

**Tumescent Solution Infiltration.** A 1 to 2 mm incision was made with a N° 11 scalpel, followed by an atraumatic cannula insertion and intradermal infiltration with a solution prepared with one adrenaline ampoule diluted in 1 000 cm<sup>3</sup> of 0.9 % NaCl solution within an infusion bag at 150 mmHg pressure and 200 cm<sup>3</sup>/minute infiltration rate. The needle movements were deliberately slow to ensure optimal tissue expansion.

**Laser-assisted lipolysis.** LAL includes several devices with varying wavelengths targeted to cause a selectively fat photo-thermolysis. This study employed a multifrequency laser lipolysis device (Lipolaser LPL9002™, Colombia) for the entire procedure. This low-power cold laser device has wavelengths of 532, 650, and 980 nanometers. This equipment complies with international safety standards for electro-medical devices (IEC 601-1) and laser equipment (IEC 825) (Table 2).

Table 2. Some Lipolaser LPL9002 technical features.

Laser	Features	Main effect
Green	A 532 nm wavelength diode-pumped solid-state laser (DPSSL) and beam diameter at the focal point of 3 mm.	Vasoconstriction
Red	This 650-670 nm wavelength laser has a combination of gallium (Ga), aluminum (Al), and arsenic (As) within the active semiconductor (GaAlAs) and a beam diameter at the focal point of 3 mm.	Adipocyte lysis
Infrared	This 980 nm wavelength laser has a combination of gallium (Ga), aluminum (Al), and arsenic (As) within the active semiconductor (GaAlAs), with a beam diameter at the focal point of 3 mm.	Skin tightening

All regions underwent the same four-step technique as follows:

- a. Green laser application. Green laser therapy is the first in laser-assisted lipolysis. Its primary function is vasoconstriction induction,

which reduces bleeding and the likelihood of fat embolus formation. The laser device is introduced through a 2 mm caliber cannula, followed by slow forward and backward cannula movements within the subcutaneous

adipose tissue, initially in a deep plane, then in an intermediate plane, and finally in the superficial plane.

- b. Red laser application. This wavelength laser aimed to induce adipocyte lysis, resulting in the release of triacyl glycerides. From a clinical point of view, the perception of the change in fat consistency by palpation (from a solid to a liquid phase) and the absence of resistance to the laser cannula passage indicates complete adipose tissue liquefaction.
- c. Fat evacuation via vacuum device. Liquid fat was aspirated using a suction device (Wells Johnson Co. Tucson, AZ, USA) with 3- 5 mm straight and curved cannulas. Slow movements were performed in the same order as during laser application, starting in the deep plane and concluding in the superficial plane. Overall, this process is minimally traumatic, resulting in the collection of liquefied, yellowish fat with minimal to no blood.
- d. Subdermal skin stimulation by Infrared Laser. This wavelength laser's function is skin tightening, resulting in its adhesion to the underlying muscle. The technique was the same as in the red laser for 3 to 6 minutes in each treated area.

#### **Early Postoperative Follow-Up**

After the surgical procedure, the incisions were sealed with Micropore® tape and covered with sterile gauze and dressings. Subsequently, a low-pressure elastic bandage was applied. After that, the patient was promptly transferred to the recovery room and closely monitored for 4 hours while undergoing a liquid food tolerance test. The patient progressed satisfactorily during the first twelve-hour period, maintaining her vital signs within normal ranges. She did not experience any complications, which led to her discharge 12 hours after surgery.

Postsurgical care sessions were initiated on the second day, encompassing hyperbaric chamber treatments, external laser therapy, pressotherapy, and a 5-minute drainage routine over five days. The patient underwent daily evaluations for ten days and monthly assessments for the subsequent three months.

#### **Postoperative Follow-Up**

During the three-month postoperative follow-up, the patient had a satisfactory progression without local or systemic complications attributable to the procedure.


Panels 2 to 3 show the impressive aesthetic improvement in the abdomen, arms, breasts, hips, and thighs due to fat tissue reduction and substantial skin tightening. It is important to highlight that the procedure left no visible scars in any surgically intervened areas.

#### **DISCUSSION**


Patients who have undergone massive weight loss face a unique aesthetic challenge due to skin redundancy and lingering fat, often resulting in visible deformities, frequently requiring the address of excess skin and fat by surgical excision (27,28). This approach addresses functional, dermatological, and psychological issues by restoring a more aesthetically pleasing contour. Notably, available evidence suggests that 70 % to 90 % of these patients express a desire for post-bariatric plastic surgery (27,29), but unfortunately, only 10 % have access to such interventions (18-21,27).

The early surgical procedures to address skin and fat excess included surgical excisions such as abdominoplasty, breast lift, brachioplasty, thigh lift, and lower body lifting. However, these procedures pose the drawback of extensive scars replacing the redundant skin, leading some patients to decline such interventions (17, 30). Fortunately, in the last 20 years, new medical technologies and surgical approaches have effectively addressed this issue, particularly refinements in liposuction and photonic treatments. In this regard, Laser-Assisted Lipolysis (LAL) is commonly used for unwanted fat removal and skin reduction (33,34).

Since its Food and Drug Administration (FDA) approval in 2006, there has been an explosive development of medical lasers with different wavelengths (924, 968, 980, 1 064, 1 319, 1 320, 1 344, and 1 440 nm) that have eventually been employed for lipolysis and



**Panel 2. A:** Redundant skin and adipose panniculus evolution one month after LAL **A:** Front view. A significant decrease in redundant skin is observed in the abdomen and arms compared with the Panel 1 photograph. A reduction in abdominal, leg, and hip fat is evident. The lift procedure with implant placement resolved breast elongation. **B:** Back view. A considerable decline in fat depots can be observed in the lower and upper back, thighs, arms, hips, and buttocks. There is an excellent improvement in gynoid lipodystrophy (celullité) in both gluteal regions.



**Panel 3.** Redundant skin and adipose panniculus evolution three months after LAL **A:** Front view. A complete redundant skin and residual fat disappearance is observed in the abdomen. **B:** Back view. Fat depots in the lower and upper back, thighs, arms, hips, and buttocks show an important decline compared to baseline and month one. The gynoid lipodystrophy (celullité) in both gluteal regions is still improving.

skin tightening (35-39) and mostly studies have supported the initial clinical observations in adiposity reduction, shorter recovery times, and improved skin retraction (40-43). In this regard, the Lipolaser LPL9002™ device employed in

this clinical case has the advantage of three low-power cold lasers at wavelengths of 532, 650, and 980 nanometers, with no need for external cooling during the surgery, thus reducing the burn

risk (44,45). This is the first device combining three (Multifrequency) low-potency level lasers for subdermal use during large-volume lipolysis and tissue-tightening treatment. Unlike external lasers, Lipolaser delivers its energy directly to the adipose tissue. An additional advantage of this technology is external therapy laser outputs at the same wavelengths for preparative skin surface application (46,47).

The rationale behind these wavelengths is the specific effects on adipose tissue and skin (48); Green 532 nm DPSSL laser effectively stimulates clothing in small vessels, thus promoting hemostasis during surgical procedures (49-51). Its ability to be absorbed by hemoglobin in blood vessels allows for precise and controlled small blood vessel sealing, minimizing blood loss, contributing to hematomas and ecchymosis prevention, faster postsurgical recovery, and enhancing patient comfort (52-54). Additionally, the DPSSL laser enables greater precision when working in delicate areas near important blood vessels, especially in body contouring and facial aesthetic surgeries with minimal thermal damage to surrounding tissues, ensuring a better surgical experience and improved recovery (55). On the other hand, the GaAlAs 650 nm red laser has demonstrated the ability to cause selective fat cell lysis during the lipolysis procedure, allowing a massive fat extraction with minimal tissue trauma (56). Alternatively, although the infrared GaAlAs 980 nm laser has been employed to break selectively fat cell membranes, this wavelength's main feature is stimulating skin's collagen formation, contributing to a skin-tightening effect (57-59).

In this vein, it can be stated that the overall effect of these three different wavelength lasers involves fat liquefaction, small blood vessel coagulation, increased fibroblast proliferation, and neo-collagen synthesis stimulation, resulting in skin tightening and increased tissue elasticity (60-62). There is a noteworthy aspect beyond lipolysis; skin volume reduction is perhaps the most significant advantage of laser lipolysis (63-65) because massive weight loss is often accompanied by structural protein alterations characterized by reduced levels of heparan sulfate, perlecan, and an increase in collagen-type III (66-68). In fact, differences in protein profiles between patients with substantial weight loss without surgery and

those post-bariatric surgeries have confirmed different skin structural phenotypes, suggesting a personalized approach in the selection of body contouring techniques.

It is now widely accepted that heparan sulfate can interact with various biomolecules, inducing biological activities such as cell proliferation, inflammation, hemostasis, and angiogenesis (68,69). For example, perlecan, also known as basement membrane-specific heparan sulfate proteoglycan core protein (HSPG) or heparan sulfate proteoglycan 2 (HSPG2) interacts with various growth factors, including vascular endothelial growth factor (VEGF)-A, essential for the epidermal formation (68,69). During Obesity and post-bariatric weight loss, perlecan concentration and physical properties could be altered, making skin less resistant to tension, for example, along the sutures line, increasing the risk of wound dehiscence, abnormal healing, and infection (70-71). On the other hand, differences in the expression of Collagen Type XIV Alpha 1 Chain (COL14A1), periplakin (PPL), and vinculin (VCL), proteins directly related to the structural composition and mechanical properties of cutaneous tissue, constitute a set of molecular alterations responsible for the distinct clinical characteristics observed between post-bariatric skin laxity (72,73). For example, COL14A1, which plays a central role in regulating the biomechanical properties of the skin, showed lower expression in post-bariatric surgery, suggesting an acquired deficiency of this collagen after bariatric surgery. COL14A1, associated with fibril-like collagen with an interrupted triple helix, controls fibrillogenesis and coordinates the structural organization of collagen types I, III, and V. In this context, PPL and VCL, among other proteins functioning in tissue architecture and regulating mechanical properties of cutaneous tissue and cell adhesion, also showed lower expression in post-bariatric surgery patients (72). PPL plays a key role in protecting and providing resistance to cutaneous tissue, while VCL is essential in the structure and function of focal adhesions and junctional complexes. Reduced availability of PPL and VCL significantly affected the regulation of stiffness in both static stabilization strength and the transmission of intercellular contractile forces, worsening skin laxity (75-80). Therefore, this patient group requires a different and comprehensive



therapeutic approach, including managing expectations related to the final aesthetic outcome based on specific clinical skin characteristics, preoperative protein supplementation protocols to improve skin conditions, development and application of techniques allowing greater removal of excess skin, and understanding changes in the skin's protein profile. Thus, the challenges of post-bariatric body contouring surgery go beyond the technical development needed to remove large amounts of excess skin.

It is noteworthy that skin tightening continues to improve several months after laser lipolysis due to the delayed nature of neo-collagenesis. This effect was observed in the present clinical case, where the final tightening effect was fully observable by the third month postoperatively. The results were excellent from an aesthetic standpoint and satisfaction, as the patient did not require a second session to achieve the desired body contour. However, it should be noted that additional skin tightening sessions may be necessary depending on factors such as age, genetics, and skin condition due to environmental factors such as smoking and sun exposure.

Laser-assisted lipolysis (LAL) offers excellent patient tolerance, rapid recovery time, reduced postoperative pain, bruising, edema, and dermal tightening. These are significant advantages of LAL compared to conventional liposuction methods (74). The coagulation of blood and lymphatic vessels and the aspiration of liquefied fat by the laser through small cannulas with less subsequent trauma may explain these benefits.

In the author's experience, complications have been a rare event. Future considerations will include more precise laser and light devices, improved technology, and a reduced side effect profile. Specifically for laser lipolysis, treatments will optimize energy production while minimizing side effects, accelerating recovery, and improving operator time.

## CONCLUSION

Patients with massive weight loss have real aesthetic concerns that must be addressed effectively, definitively, and safely. They

exhibit varying skin redundancy, fat involution, and localized hypertrophy persistence. Traditional methods to address these problems involved excision, lifting, and even volumetric reconstruction. These procedures inevitably result in a patient transitioning from a high body mass index to a low body mass index but with the marks of scars. Laser lipolysis techniques with skin tightening represent a recent era in plastic surgery that has demonstrated efficacy and safety in body contouring for patients without massive weight loss.

**Conflict of Interest:** The authors declare no conflicts of interest.

## REFERENCES

1. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of Obesity and a call to action: As its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. *Metabolism*. 2022;133:155217.
2. Jackson SE, Llewellyn CH, Smith L. The obesity epidemic—Nature via nurture: A narrative review of high-income countries. *SAGE open medicine*. 2020;8:2050312120918265.
3. Jaacks LM, Vandevijvere S, Pan A, McGowan CJ, Wallace C, Imamura F, et al. The obesity transition: Stages of the global epidemic. *Lancet Diab Endocrinol*. 2019;7(3):231-240.
4. Apovian CM. Obesity: Definition, comorbidities, causes, and burden. *Am J Manag Care*. 2016;22(7 Suppl):S176-185.
5. Bouchard C. Genetics of Obesity: What We Have Learned Over Decades of Research. *Obesity (Silver Spring)*. 2021;29(5):802-820.
6. Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: From Obesity to metabolic syndrome and diabetes. *Diabetol Metab Syndr*. 2020;12(1):1-20.
7. Rendell MS. Obesity and diabetes: The final frontier. *Expert Rev Endocrinol Metab*. 2023;18(1):81-94.
8. Shariq OA, McKenzie TJ. Obesity-related hypertension: A review of pathophysiology, management, and the role of metabolic surgery. *Gland Surg*. 2020;9(1):80-93.
9. Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. Obesity and dyslipidemia. *Metabolism*. 2019;92:71-81.

10. Bermúdez V, Durán P, Rojas E, Díaz MP, Rivas J, Nava M, et al. The Sick Adipose Tissue: New Insights Into Defective Signaling and Crosstalk With the Myocardium. *Front Endocrinol (Lausanne)*. 2021;12:735070.
11. Mafort TT, Rufino R, Costa, CH, Lopes AJ. Obesity: Systemic and pulmonary complications, biochemical abnormalities, and impairment of lung function. *Multidiscip Respir Med*. 2016;11:28.
12. Kulkarni K, Karssiens T, Kumar V, Pandit H. Obesity and osteoarthritis. *Maturitas*. 2016;89:22-28.
13. Chávez-Castillo M, Duran P, Garrido B, Díaz A, Escalona D, Cano C. Obesity as a Neurobiologic Disorder: A Heavyweight Contender. *Current Psychiatry Research and Reviews Formerly: Current Psych Rev*. 2023;19(2):109-136.
14. Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and cancer: A current overview of epidemiology, pathogenesis, outcomes, and management. *Cancers*. 2023;15(2):485.
15. Morigny P, Boucher J, Arner P, Langin D. Lipid and glucose metabolism in white adipocytes: Pathways, dysfunction and therapeutics. *Nature Rev Endocrinol*. 2021;17(5):276-295.
16. Kachare MD, Barrow BE, Sozer SO. Secondary Body Contouring. *Clin Plast Surg*. 2024;51(1):P173-190.
17. Santiago EA, Andrighetti TC, Meroni MLM, Nolasco TF, Contente R, Souza CL. As principais técnicas utilizadas de abdominoplastia em pacientes pós-bariátricos após massiva perda de peso: Revisão sistemática. *Rev Bras Cir Plást*. 2023;38(1):e0610.
18. Kitzinger HB, Abayev S, Pittermann A, Karle B, Bohdjalian A, Langer FB, et al. After massive weight loss: patients' expectations of body contouring surgery. *Obes Surg*. 2012;22(4):544-548.
19. Giordano S, Victorzon M, Koskivuo I, Suominen E. Physical discomfort due to redundant skin in post-bariatric surgery patients. *J Plast Reconstr Aesthet Surg*. 2013;66(7):950-955.
20. Aldaqal SM, Makhdoum AM, Turki AM, Awan BA, Samargandi OA, Jamjom H. Post-bariatric surgery satisfaction and body-contouring consideration after massive weight loss. *N Am J Med Sci*. 2013;5(4):301-305.
21. Björserud C, Olbers T, Fagevik Olsén M. Patients' experience of surplus skin after laparoscopic gastric bypass. *Obes Surg*. 2011;21(3):273-277.
22. Baillet A, Asselin M, Comeau E, Méziat-Burdin A, Langlois MF. Impact of excess skin from massive weight loss on the practice of physical activity in women. *Obes Surg*. 2013;23(11):1826-1834.
23. Gilmartin J. Body image concerns amongst massive weight loss patients. *J Clin Nurs*. 2013;22(9/10):1299-1309.
24. Orpheu SC, Coltro PS, Scopel GP, Gomez DS, Rodrigues CJ, Modolin ML, et al. Collagen and elastic content of abdominal skin after surgical weight loss. *Obesity Surg*. 2010;20:480-486.
25. Toninello P, Montanari A, Bassetto F, Vindigni V, Paoli A. Nutritional Support for Bariatric Surgery Patients: The Skin beyond the Fat. *Nutrients*. 2021;13(5):1565.
26. de Sousa N, Vieira I, Quagliotti Durigan JL, Sanchez Ramos da Silva A, Cássia Marqueti R. Adipose Tissue Extracellular Matrix Remodeling in Response to Dietary Patterns and Exercise: Molecular Landscape, Mechanistic Insights, and Therapeutic Approaches. *Biology*. 2022;11(5):765.
27. Klassen AF, Cano SJ, Scott A, Johnson J, Pusic AL. Satisfaction and quality-of-life issues in body contouring surgery patients: A qualitative study. *Obes Surg*. 2012;22(10):1527-1534.
28. Lyons K, Meisner BA, Sockalingam S, Cassin SE. Body image after bariatric surgery: A qualitative study. *Bariatric Surg Pract Patient Care*. 2014;9(1):41-49.
29. Gusenoff JA, Messing S, O'Malley W, Langstein HN. Patterns of plastic surgical use after gastric bypass: Who can afford it and who will return for more. *Plast Reconstr Surg*. 2008;122(3):951-958.
30. Sioka E, Tzovaras G, Katsogridaki G, Bakalis V, Bampalitsa S, Zachari E, et al. Desire for body contouring surgery after laparoscopic sleeve gastrectomy. *Aesthet Plast Surg*. 2015;39(6):978-984.
31. Song AY, Rubin JP, Thomas V, Dudas JR, Marra KG, Fernstrom MH. Body image and quality of life in post massive weight loss body contouring patients. *Obesity (Silver Spring)*. 2006;14(9):1626-1636.
32. Modarressi A, Balagué N, Huber O, Chilcott M, Pittet-Cuénod B. Plastic surgery after gastric bypass improves long-term quality of life. *Obes Surg*. 2013;23(1):24-30.
33. Lee JY, Oh SW, Ryu HY, Seo YS. Development of a Minimally Invasive and Non-invasive Lipolysis Laser System for Effective Fat Reduction. *J Lasers Med Scienc*. 2021;12:e55.
34. Wolska J, Hassan H. Noninvasive lipolysis modalities in aesthetic medicine. *J Cosmetic Dermatol*. 2023;22(10):2635-2649.
35. McBean JC, Katz BE. Laser lipolysis: An update. *J Clin Aesthet Dermatol*. 2011;4(7):25-34.
36. Shapira E, Plonski L, Menashe S, Ofek A, Rosenthal A, Brambilla M, et al. High-Quality Lipoaspirate Following 1 470-nm Radial Emitting Laser-Assisted Liposuction. *Ann Plast Surg*. 2022;89(6):e60-e68.
37. Chia CT, Albert MG, Del Vecchio S, Theodorou SJ. 1 000 Consecutive Cases of Laser-Assisted Liposuction Utilising the 1 440 nm Wavelength Nd: YAG Laser: Assessing the Safety and Efficacy. *Aesthetic Plast Surg*. 2017;42(1):9-12.

38. Žgaljardić Z, Žgaljardić I. Laser-Assisted Liposuction in Body Contouring. In *Body*
39. Hamblin MR. Photobiomodulation or low-level laser therapy. *J Biophotonics*. 2016;9(11-12):1122.
40. Schavelzon DE, Blugerman G, Chomyszyn A. Laserlipolysis. *Liposuction: Principles and Practice*. 2016:377-383.
41. Chen Y, Huang J, Xia S, Wang K, Rui Y. Effect of laser energy on protein conformation and lipid structure in skin tissue. *Optics Laser Technol*. 2023;160:109077.
42. Musstaf RA, Jenkins DF, Jha AN. Assessing the impact of low-level laser therapy (LLLT) on biological systems: A review. *Internat J Radiat Biol*. 2019;95(2):120-143.
43. Magni G, Pieri L, Fusco I, Madeddu F, Zingoni T, Rossi F. Laser emission at 675 nm: *In vitro* study evidence of a promising role in skin rejuvenation. *Regenerative Therapy*. 2023;22:176-180.
44. Mansouri V, Arjmand B, Tavirani MR, Razzaghi M, Rostami-Nejad M, Hamdih M. Evaluation of efficacy of low-level laser therapy. *J Lasers Med Scienc*. 2020;11(4):369.
45. Beigvand HH, Razzaghi M, Rostami-Nejad M, Rezaei-Tavirani M, Safari S, Rezaei-Tavirani M, et al. Assessment of laser effects on skin rejuvenation. *J Lasers Med Scienc*. 2020;11(2):212.
46. Vas K, Besenyi Z, Urbán S, Badawi A, Pávics L, Erős G, et al. Efficacy and safety of long pulse 1064 and 2940 nm lasers in noninvasive lipolysis and skin tightening. *J Biophotonics*. 2019;12(9):e201900083.
47. Jankowski M, Gawrych M, Adamska U, Ciescinski J, Serafin Z, Czajkowski R. Low-level laser therapy (LLLT) does not reduce subcutaneous adipose tissue by local adipocyte injury but rather by modulation of systemic lipid metabolism. *Lasers Med Scienc*. 2017;32:475-479.
48. Meko MS. Laser Liposuction-Skin Tightening in Body Contouring of Massive Weight Loss Patients. *Egyptian J Plast Reconstr Surg*. 2018;42(2):317-322.
49. Kannengiesser C, Ostroumov V, Pfeufer V, Seelert W, Simon C, von Elm R, Zuck A. Ten years optically pumped semiconductor lasers: Review, state-of-the-art, and future developments. *Solid State Lasers XIX: Technology and Devices*. 2010;7578:239-249.
50. Black JF, Barton JK. Time-domain optical and thermal properties of blood undergoing laser photocoagulation. In *Laser-tissue interaction XII: photochemical, photothermal, and photomechanical*. SPIE. 2001;4257:341-354.
51. Bornes L, Windoffer R, Leube RE, Morgner J, van Rheenen J. Scratch-induced partial skin wounds re-epithelialise by sheets of independently migrating keratinocytes. *Life Sci Alliance*. 2020;4(1):e202000765.
52. Kannengiesser C, Ostroumov V, Pfeufer V, Seelert W, Simon C, von Elm R, Zuck A. Ten years optically pumped semiconductor lasers: Review, state-of-the-art, and future developments. *Solid State Lasers XIX: Technology and Devices*. 2010;7578:239-249.
53. Azadgoli B, Baker RY. Laser applications in surgery. *Ann Translat Med*. 2016;4(23):452.
54. Yoshida N, Sano Y. History, clinical application, and future perspective of narrow band imaging and blue laser imaging. *Digest Endosc*. 2022;34:86-90.
55. Hulicius E, Kubeček V. Semiconductor lasers for medical applications. In *Lasers for Medical Applications*. Woodhead Publishing. 2013:222-250.
56. Avci P, Nyame TT, Gupta GK, Sadasivam M, Hamblin MR. Low-level laser therapy for fat layer reduction: A comprehensive review. *Lasers Surg Med*. 2013;45(6):349-357.
57. Al-Timimi ZA. The performance of the cold laser therapy (GaAlAs-980nm). *Pakistan J Med Health Scienc*. 2021;15(10):3096-3102.
58. Serrage H, Heiskanen V, Palin WM, Cooper PR, Milward MR, Hadis M, et al. Under the spotlight: Mechanisms of photobiomodulation concentrating on blue and green light. *Photoch Photobiol Scienc*. 2019;18(8):1877-1909.
59. Fried N, Seeber F, MacGregor T. *Therapeutic Applications of Lasers*. 2021.
60. Neira R, Arroyave J, Ramírez H, Ortiz CL, Solarte E, Sequeda F, et al. Fat liquefaction: Effect of low-level laser energy on adipose tissue. *Plast Reconstr Surg*. 2002;110(3):912-922 (discussion 23-5).
61. Decorato JW, Chen B, Sierra R. Subcutaneous adipose tissue response to a non-invasive hyperthermic treatment using a 1060 nm laser. *Lasers Surg Med*. 2017;49(5):480-489.
62. Alizadeh Z, Halabchi F, Bodaghabadi Z, Zarandi MM, Abolhasani M, Seifi V, et al. Non-invasive Body Contouring Technologies: An Updated Narrative Review. *Aesth Plast Surg*. 2023; <https://doi.org/10.1007/s00266-023-03647-x>
63. Avci P, Gupta A, Sadasivam M, Vecchio D, Pam Z, Pam N, et al. Low-level laser (light) therapy (LLLT) in skin: Stimulating, healing, restoring. In *Semin Cutan Med Surg*. 2013;32(1):41.
64. Mazzoni D, Lin MJ, Dubin DP, Khorasani H. Review of non-invasive body contouring devices for fat reduction, skin tightening and muscle definition. *Australasian J Dermatol*. 2019;60(4):278-283.
65. Oni G, Hoxworth R, Teotia S, Brown S, Kenkel JM. Evaluation of a microfocused ultrasound system for improving skin laxity and tightening in the lower face. *Aesthetic Surgery J*. 2014;34(7):1099-1110.
66. Veiga DF, Bussolaro RA, Kobayashi EY, Medeiros VP, Martins JRM, Garcia EB, et al. Glycosamino-

- glycans of abdominal skin after massive weight loss in post-bariatric female patients. *Obes Surg.* 2011;21(6):774-782.
67. Yamashita Y, Nakada S, Yoshihara T, Nara T, Furu-ya N, Miida T, et al. Perlecan, a heparan sulfate proteoglycan, regulates systemic metabolism with dynamic changes in adipose tissue and skeletal muscle. *Scientific reports.* 2018;8(1):7766.
  68. Yamashita Y, Nakada S, Yoshihara T, Nara T, Furu-ya N, Miida T, et al. Perlecan, a heparan sulfate proteoglycan, regulates systemic metabolism with dynamic changes in adipose tissue and skeletal muscle. *Scientific reports.* 2018;8(1):7766.
  69. Xie M, Li JP. Heparan sulfate proteoglycan—a common receptor for diverse cytokines. *Cellular signalling.* 2019;54:115-21.
  70. Manzoni AP, Weber MB. Skin changes after bariatric surgery. *A Bras Dermatol.* 2015;90(2):157-166.
  71. Annaval T, Wild R, Créton Y, Sadir R, Vivès RR, Lortat-Jacob H. Heparan Sulfate Proteoglycans Biosynthesis and Post Synthesis Mechanisms Combine Few Enzymes and Few Core Proteins to Generate Extensive Structural and Functional Diversity. *Molecules.* 2020;25(18):4215.
  72. Gallo JRB, Maschio-Signorini LB, Cabral CRB, de Campos Zuccari DAP, Nogueira ML, Bozola AR, et al. Skin Protein Profile after Major Weight Loss and Its Role in Body Contouring Surgery. *Plast Reconstr Surg Glob Open.* 2019;7(8):e2339.
  73. Halawi A, Abiad F, Abbas O. Bariatric surgery and its effects on the skin and skin diseases. *Obes Surg.* 2013;23:408-413.
  74. Fawzy A, Oke Putranti I, Sylvina Amri M. A Review: Insights of Aesthetic Refinement after Bariatric Surgery and Massive Weight Loss. *International J Med Sci Clin Res Stud.* 2023;3(4):655-665.
  75. Mierke CT. The role of vinculin in the regulation of the mechanical properties of cells. *Cell Biochem Biophys.* 2009;53:115-126.
  76. Diez G, Kollmannsberger P, Mierke CT, Koch TM, Vali H, Fabry B, et al. Anchorage of vinculin to lipid membranes influences cell mechanical properties. *Biophys J.* 2009;97:3105-3112.
  77. Carisey A, Ballestrem C. Vinculin, an adapter protein in control of cell adhesion signalling. *Eur J Cell Biol.* 2011;90:157-163.
  78. Carisey A, Tsang R, Greiner AM, Nijenhuis N, Heath N, Nazgiewicz A, et al. Vinculin regulates the recruitment and release of core focal adhesion proteins in a force-dependent manner. *Curr Biol.* 2013;23(4):271-281.
  79. Humphries JD, Wang P, Streuli C, Geiger B, Humphries MJ, Ballestrem C. Vinculin controls focal adhesion formation by direct interactions with talin and actin. *J Cell Biol.* 2007;179:1043-1057.
  80. Boczonadi V, McInroy L, Määttä A. Cytolinker cross-talk: Periplakin N-terminus interacts with plectin to regulate keratin organisation and epithelial migration. *Exp Cell Res.* 2007;313:3579-3591.